KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables: 2013-2024

Historic Receivables for Rigel Pharmaceuticals (RIGL) over the last 10 years, with Dec 2024 value amounting to $41.6 million.

  • Rigel Pharmaceuticals' Receivables rose 50.39% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.6 million, marking a year-over-year increase of 11.13%. This contributed to the annual value of $41.6 million for FY2024, which is 36.22% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Receivables of $41.6 million as of FY2024, which was up 36.22% from $30.6 million recorded in FY2023.
  • Rigel Pharmaceuticals' Receivables' 5-year high stood at $41.6 million during FY2024, with a 5-year trough of $15.5 million in FY2021.
  • Its 3-year average for Receivables is $30.7 million, with a median of $30.6 million in 2023.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Receivables spiked by 57.98% in 2020, and later decreased by 3.14% in 2021.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Receivables stood at $16.0 million in 2020, then declined by 3.14% to $15.5 million in 2021, then climbed by 29.27% to $20.0 million in 2022, then skyrocketed by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024.